Abstract
The introduction of intrathecal baclofen therapy in 1985 (Penn and Kroin 1985; Ochs and Struppler 1987) brought significant progress in treating severe forms of spasticity. With this new therapy, high drug concentrations are reached at the desired site of action in the lumbar spinal cord while the concentration in the brain remains very low. Thus, side effects from actions at the cerebral level, such as tiredness and hallucinations, can be circumvented. The concentration of baclofen in the CSF is 50 times higher with intrathecal administration than with systemic administration (Kroin 1992).
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Farkas S, Tarnawa I, Berzsenyi P (1989) Effect of some centrally acting muscle relaxants on spinal root potentials: a comparative study. Neuropharmacology 28:161–173
Green KA, Cottrell GA (1988) Actions of baclofen on components of the Ca-current in rat and mouse DRG neurones in culture. Br J Pharmacol 94:235–245
Jimenez I, Rudomin P, Enriquez M (1991) Different effects of (-)-baclofen on la and descending monosynaptic EPSPs. Exp Brain Res 85:103–113
Kroin J (1992) Intrathecal drug administration: present use and future trend. Clin Pharmacokinet 22:319–336
Läzorthes Y, Sallerin-Caute B, Verdie JC, Bastide R, Carillo JP (1990) Chronic intrathecal baclofen administration for control of severe spasticity. J Neurosurg 72:393–402
Lev-Tov A, Meyers DER, Burke RE (1988) Activation of GABA-B receptors in the intact mammalian spinal cord mimics the effects of reduced presynaptic Ca++ influx. Proc Natl Acad Sci USA 85:5330–5333
MacDonell RAL, Talalla A, Swash M, Grundy D (1989) Intrathecal baclofen and the H-reflex. J Neurol Neurosurg Psychiatry 52:1110–1112
Meinck HM, Benecke R, Küster S, Conrad B (1983) Cutaneomuscular (flexor) reflex organization in normal man and in patients with motor disorders. Adv Neurol 39:787–796
Ochs G, Struppler A (1987) Treatment of spasticity by implantable drug administration devices and intrathecal catheter. In: Benecke R, Conrad B, Marsden CD (eds) Motor disturbances I. Academic, London, pp 197–208
Penn RD, Kroin JS (1985) Continuous intrathecal baclofen for severe spasticity. Lancet 2:125–127
Price GW, Kelly JS, Bowery NG (1987) The location of GABA-B receptor binding sites in mammalian spinal cord. Synapse 1:530–538
Sallerin-Caute B, Lazorthes Y, Monsarrat B, Cros J, Bastide R (1991) CSF baclofen levels after intrathecal administration in severe spasticity. Eur J Clin Pharmacol 40:363–365
Wang MY, Dun NJ (1990) Phaclofen-insensitive presynaptic inhibitory action of (+/-)-baclofen in neonatal rat motoneurons in vitrol. Br J Pharmacol 99:413–421
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1993 Springer-Verlag Berlin Heidelberg
About this paper
Cite this paper
Dressnandt, J., Konstanzer, A., Conrad, B. (1993). Dynamics of Reflex Excitability Following Intrathecal Baclofen Administration in Patients with Severe Spastic Syndromes. In: Thilmann, A.F., Burke, D.J., Rymer, W.Z. (eds) Spasticity. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-78367-8_29
Download citation
DOI: https://doi.org/10.1007/978-3-642-78367-8_29
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-78369-2
Online ISBN: 978-3-642-78367-8
eBook Packages: Springer Book Archive